Fig. 1. HFD-induced obesity and fatty liver is attenuated by Atractylodes lancea treatment. (A) Schematic of the experimental design. Mice were maintained on a normal diet (ND) or high-fat diet (HFD) for 12 weeks, and 30 mg/kg, 60 mg/kg, or 120 mg/kg of Atractylodes lancea (AL) was administered orally during the final 4 weeks of HFD feeding (n=7-10, each group). (B) Mouse body weight at the end of the study. (C) White adipose tissue (WAT) and liver weight. (D) Serum triglyceride (TG) and total cholesterol levels. (E) Serum alanine aminotransferase (ALT) levels. (F) Representative images of Hematoxylin and eosin (H&E) and Oil Red O staining in the liver. Scale bar (H&E): 500 μm, scale bar (ORO): 60 μm. (G) RT-qPCR analyses of Srebf1 and Dgat2 mRNA levels from the mouse liver. (H) Immunoblot analysis showing the expression levels of fatty acid synthase (FAS) protein in the liver tissues from HFD-fed mice treated with Atractylodes lancea compared to vehicle (Veh)-treated controls. Data are presented as mean ± SEM (n=7-10). Statistical analysis was performed using one-way ANOVA with Tukey’s post-hoc test. **p<0.01, ***p<0.001: compared with ND+Veh; #p<0.05, ##p<0.01, ###p<0.001: compared with HFD+Veh.
© Biomolecules & Therapeutics
